21st Austria weekly - Valneva, Austrian Post, UBM (02/12/2021)
21st Austria weekly - Valneva Austrian Post UBM 02/12/2021 [pic1]Valneva: Austrian/French a specialty vaccine company today confirmed that the European Medicines Agency EMA has started rolling review of VLA2001 its whole-virus inactivated adjuvanted COVID-19 candidate. Valneva remains focused on achieving regulatory approvals VLA2001 following positive Phase 3 trial results. The Company continues to make progress with submission in UK MHRA